HK1097777A1 - Medicinal aerosol formulation - Google Patents

Medicinal aerosol formulation

Info

Publication number
HK1097777A1
HK1097777A1 HK07105448.0A HK07105448A HK1097777A1 HK 1097777 A1 HK1097777 A1 HK 1097777A1 HK 07105448 A HK07105448 A HK 07105448A HK 1097777 A1 HK1097777 A1 HK 1097777A1
Authority
HK
Hong Kong
Prior art keywords
aerosol formulation
medicinal aerosol
amino acid
medicinal
propellant
Prior art date
Application number
HK07105448.0A
Other languages
English (en)
Inventor
Akwete Adjei
Anthony J Cutie
Original Assignee
Aeropharm Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22567809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1097777(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aeropharm Technology Inc filed Critical Aeropharm Technology Inc
Publication of HK1097777A1 publication Critical patent/HK1097777A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK07105448.0A 1998-09-22 2007-05-23 Medicinal aerosol formulation HK1097777A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09158369 US6136294C1 (en) 1998-09-22 1998-09-22 Amino acid stabilized medical aerosol formulation

Publications (1)

Publication Number Publication Date
HK1097777A1 true HK1097777A1 (en) 2007-07-06

Family

ID=22567809

Family Applications (2)

Application Number Title Priority Date Filing Date
HK02103508A HK1041835A1 (en) 1998-09-22 2002-05-08 Medicinal aerosol formulation
HK07105448.0A HK1097777A1 (en) 1998-09-22 2007-05-23 Medicinal aerosol formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK02103508A HK1041835A1 (en) 1998-09-22 2002-05-08 Medicinal aerosol formulation

Country Status (15)

Country Link
US (1) US6136294C1 (xx)
EP (2) EP1123120B1 (xx)
JP (1) JP2002526459A (xx)
CN (1) CN100337614C (xx)
AT (2) ATE505184T1 (xx)
AU (1) AU745554B2 (xx)
CA (1) CA2344816C (xx)
CY (1) CY1105538T1 (xx)
DE (2) DE69932835T2 (xx)
DK (1) DK1123120T3 (xx)
ES (1) ES2267288T3 (xx)
HK (2) HK1041835A1 (xx)
MX (1) MXPA01002894A (xx)
PT (1) PT1123120E (xx)
WO (1) WO2000016814A1 (xx)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6362225B1 (en) * 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
AU783120B2 (en) * 2000-01-25 2005-09-29 Aeropharm Technology, Inc. A medicinal aerosol formulation
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US6565833B1 (en) * 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
CZ303833B6 (cs) * 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosolový prostredek
AU2001247123A1 (en) * 2000-07-19 2002-02-05 Aeropharm Technology, Inc. A medicinal aerosol formulation
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
BRPI0113042B8 (pt) * 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) * 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
BR0209271A (pt) * 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
US20040248867A1 (en) * 2001-06-12 2004-12-09 Keith Biggadike Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
WO2003028653A2 (en) * 2001-10-03 2003-04-10 Glaxo Group Limited Sustained release pharmaceutical compositions
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
AU2002361850A1 (en) * 2001-12-21 2003-07-30 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
JP4959919B2 (ja) * 2001-12-21 2012-06-27 スリーエム イノベイティブ プロパティズ カンパニー 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物
DE60228615D1 (de) * 2001-12-21 2008-10-09 3M Innovative Properties Co Medizinische aerosolzusammensetzungen mit einer eine amid- und/oder estergruppe enthaltenden exzipientenverbindung
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
AU2003217623A1 (en) * 2002-02-20 2003-09-09 Sepracor Inc. Amino acid and peptide-modified forms of glucocorticoids
US7138136B2 (en) * 2002-03-05 2006-11-21 Cleveland State University Agglomerated particles for aerosol drug delivery
US20030199594A1 (en) * 2002-04-23 2003-10-23 Rasik Shah Helium propellant composition for use with aerosols
US20050203217A1 (en) * 2002-04-30 2005-09-15 Pomrink Gregory J. Stabilizers for polymerizable biocompatible materials
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CN1292748C (zh) * 2003-03-05 2007-01-03 南昌弘益科技有限公司 噻托溴铵吸入粉雾剂及其制备工艺
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
CA2664251A1 (en) 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Isovaline for treatment of pain
GB0620700D0 (en) * 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve
AU2013363218B2 (en) 2012-12-17 2018-03-15 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN106138014A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有糖皮质激素的气雾剂药物组合物
CN106137964A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有丙酸倍氯米松的气雾剂药物组合物
CN106137965A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有环索奈德的气雾剂药物组合物
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN110302184B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 赖氨酸在季铵盐类m受体拮抗剂气雾剂中的应用
CN110302158B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 一种噻托溴铵气雾剂组合物及其制备方法
CN110302157B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 一种异丙托溴铵气雾剂组合物及其制备方法
CN110742875B (zh) * 2018-07-05 2022-09-30 北京盈科瑞创新药物研究有限公司 一种吸入用吡非尼酮溶液制剂及其制备方法和应用
CN110755414A (zh) * 2019-11-12 2020-02-07 南京华盖制药有限公司 一种酒石酸阿福特罗气雾剂及其制备方法
GB2614901A (en) * 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (xx) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3261748A (en) * 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US4129603A (en) * 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
AU5194990A (en) * 1989-02-23 1990-09-26 Rorer International (Holdings), Inc. Therapeutic aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
NZ243061A (en) * 1991-06-10 1993-09-27 Schering Corp Aerosol containing a medicament and 1,1,1,2,3,3,3-heptafluoropropane
IL103238A (en) * 1991-09-25 1995-07-31 Fisons Plc Pressed aerosol preparations
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
GB9202522D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
AU679511B2 (en) * 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
ATE233544T1 (de) * 1993-12-02 2003-03-15 Abbott Lab Aerosole als darreichungsform mit cfc-freiem treibmittel
CN1069192C (zh) * 1994-04-21 2001-08-08 王世立 一种气溶胶制剂及其配制方法
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
ATE287703T1 (de) * 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit

Also Published As

Publication number Publication date
DE69943360D1 (de) 2011-05-26
ES2267288T3 (es) 2007-03-01
EP1731140A2 (en) 2006-12-13
ATE505184T1 (de) 2011-04-15
CN1328473A (zh) 2001-12-26
HK1041835A1 (en) 2002-07-26
EP1731140A3 (en) 2007-06-27
ATE336268T1 (de) 2006-09-15
DK1123120T3 (da) 2006-10-02
EP1123120B1 (en) 2006-08-16
AU745554B2 (en) 2002-03-21
JP2002526459A (ja) 2002-08-20
EP1123120A4 (en) 2003-07-23
CA2344816C (en) 2011-05-24
US6136294C1 (en) 2002-09-24
MXPA01002894A (es) 2002-06-04
CY1105538T1 (el) 2010-07-28
EP1123120A1 (en) 2001-08-16
CA2344816A1 (en) 2000-03-30
AU5926799A (en) 2000-04-10
PT1123120E (pt) 2006-10-31
DE69932835D1 (de) 2006-09-28
US6136294A (en) 2000-10-24
DE69932835T2 (de) 2007-02-01
WO2000016814A1 (en) 2000-03-30
EP1731140B1 (en) 2011-04-13
CN100337614C (zh) 2007-09-19

Similar Documents

Publication Publication Date Title
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
MXPA03000442A (es) Una formulacion medicinal en aerosol.
EP1135173A4 (en) MEDICINAL AEROSOL FORMULATION
GB2354007B (en) Pharmaceutical formulation of fluticasone propionate
BG104130A (en) Aqueous aerosol forms containing biologically active macromolecules, and method for the preparation of the respective aerosols
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
CA2497171A1 (en) Water stabilized medicinal aerosol formulation
GB0016876D0 (en) Novel formulation
UA70921C2 (uk) Похідні 2-(імінометил)амінофенілу, спосіб їх одержання (варіанти) та фармацевтична композиція, що містить ці сполуки
WO1998008517A3 (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
HUP0003207A3 (en) Proliposome powders for inhalation stabilised by tocopherol, pharmaceutical compositions containing the same and the use of them
WO2002007672A3 (en) A medicinal aerosol formulation
AU1534501A (en) Pharmaceutical formulations of salmeterol
MX9707238A (es) Formulaciones en aerosol de butixocort.
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate